FREDERICK, Md., May 10, 2023 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that Medhealth Outlook has recognized TOMI as one of the Top 10 Infection Solution Providers of 2023 in the recent infection control solutions special edition, which can be found here.
TOMI was selected by a panel of healthcare experts, CEOs and medical practitioners, based on their advanced infection control solutions, commitment to innovation, and customer satisfaction. The company’s disinfection solution is a game-changer in the industry, providing superior disinfection performance in a fraction of the time compared to traditional disinfection methods.
“We are pleased to recognize TOMI Environmental Solutions as one of the Top Infection Control Solution Providers of 2023,” said Vishnu Santhosh, Managing Editor, Medhealth Outlook. “The COVID-19 pandemic has highlighted the need for effective infection control solutions, and TOMI Environmental Solutions has risen to the challenge with its advanced disinfection system. TOMI’s commitment to research and development has resulted in a solution that delivers exceptional results, while also being safe and easy to use.”
“We are honored to be recognized by Medhealth Outlook as one of the Top 10 Infection Control Solution Providers of 2023,” said Dr. Halden Shane, CEO of TOMI Environmental Solutions. “Our mission has always been to develop innovative offerings that provide superior infection control performance and simplify the disinfection process for our customers. This recognition is a testament to our commitment to delivering the best possible solutions to our clients.”
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to market opportunities of TOMI’s products. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that could affect our performance and cause results to differ materially from management’s expectations are described in the section entitled “Risk Factors,” in our Annual Report on Form 10-K and other SEC filings. These factors include: our history of losses that may prevent us from achieving profitability in the future; our lack of long-term customer contracts and our inability to rely on our sales history or backlog as an indicator of our future sales; that we are subject to a variety or risks associated with doing business internationally; our success in business depends on our ability to adequately protect our intellectual property; and that our stock price is volatile and there is a limited market for our shares. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Jennifer Belodeau
IMS Investor Relations
The multi-year, CDC-funded program partners public health agencies with CRISP Shared Services to provide industry-leading…
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare…
By Hari Prasad, Founder and CEO of Yosi Health Hari Prasad In today's digital age,…
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#Interoperability--Netsmart, a leading provider of healthcare technology solutions and services for community-based…
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#Interoperability--Netsmart, a leading provider of healthcare technology solutions and services for community-based…
Innovaccer integrates its Provider Copilot with athenahealth EHR to automate clinical documentation, generate potential diagnoses,…